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Abstract
Background—Intravenous recombinant tissue plasminogen activator (IV rtPA) is recommended 
treatment for acute ischemic stroke patients, but the cost-effectiveness of IV rtPA within different 
time windows after the onset of acute ischemic stroke is not well reviewed.
Aims—To conduct a literature review of the cost-effectiveness studies about IV rtPA by treatment 
times.
Summary of review—A literature search was conducted using MEDLINE, EMBASE, 
CINAHL and Cochrane Library, with the key words acute ischemic stroke, tissue plasminogen 
activator, cost, economic benefit, saving, and incremental cost-effectiveness analysis. The review 
is limited to original research articles published during 1995–2016 in English-language peer-
reviewed journals. We found 16 studies meeting our criteria for this review. Nine of them were 
cost-effectiveness studies of IV rtPA treatment within 0–3 hours after stroke onset, 2 studies within 
3–4.5 hours, 3 studies within 0–4.5 hours, and 2 study within 0–6 hours. IV rtPA is a cost-saving 
or a cost-effectiveness strategy from most of the study results. Only one study showed incremental 
cost-effectiveness ratio of IV rtPA within one year was marginally above $50,000 per QALY 
threshold. IV rtPA within 0–3 hours after stroke led to cost savings for lifetime or 30 years, and IV 
rtPA within 3–4.5 hours after stroke increased costs but still was cost-effective.
Conclusions—The literature generally showed that intravenous IV rtPA was a dominant or a 
cost-effective strategy compared to traditional treatment for acute ischemic stroke patients without 
IV rtPA. The findings from the literature lacked generalizability because of limited data and 
various assumptions.
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1. Introduction
Stroke is a serious brain injury that can result in permanent disability and death. The burden 
of stroke, including the absolute numbers of incidence and death, increased during the last 
decade.(1) Globally, an estimated 33 million strokes occurred and 5.8 million individuals 
died from stroke in 2010.(1, 2) In addition, around 5 million stroke survivors have 
permanent disability.(2) In 2010, the estimated total cost of stroke, including direct medical 
cost and indirect cost, was $53.9 billion in the US and €64.1 billion in Europe.(3, 4) 
Approximately 70% of strokes are ischemic worldwide while the proportion of ischemic 
stroke varies by race/ethnicity and region.(1, 5)
To reduce the burden associated with stroke, investigations of cost-effectiveness of available 
treatments for stroke patients such as intravenous (IV) injection of recombinant plasminogen 
activator (rtPA) are necessary. Since the US Food and Drug Administration (FDA) approval 
in 1996, rtPA remains the only thrombolytic agent approved for acute ischemic stroke in the 
US.(6) IV rtPA has been shown to improve health outcomes after stroke (7, 8).
In the past two decades, there have been some cost-effectiveness studies on IV rtPA. For 
instance, Fagan and her colleagues showed that IV rtPA within 3 hours after the onset of 
stroke saved cost associated with stroke treatment as well as improved outcomes from stroke 
in their 1998 study.(9) Additionally, we found three review articles on the cost-effectiveness 
of IV rtPA for acute ischemic stroke.(10–12) All of them reviewed studies published prior 
2008.(10–12) Since the new guidelines of IV rtPA between 3 and 4.5 hours after the onset of 
acute ischemic stroke from American Heart Association/American Stroke Association 
(AHA/ASA) as well as similar new recommendations from other organizations in Europe or 
Australia were released in late 2000s and early 2010s(13–16), and the cost-effectiveness of 
IV rtPA for the extended time windows, within 4.5 hours after the onset of stroke, has never 
been examined, an up-to-date review of economic impact of IV rtPA is needed to better 
understand the cost-effectiveness of IV rtPA under various treatment conditions. Thus, we 
conducted a literature review of cost-effectiveness of IV rtPA published up to 2014.
2. Methods
We performed a comprehensive literature search of peer-reviewed journal articles published 
in English between January 1995 and December 2016 by using the databases MEDLINE, 
EMBASE, CINAHL and Cochrane Library. We augmented the search by using Google 
Scholar and checking the references of the articles we obtained. The strategy used for the 
search included keywords in stroke and rtPA treatment including acute ischemic stroke, 
tissue plasminogen activator and rtPA, and keywords in cost-effectiveness analyses including 
cost, economic, benefit, effectiveness and ICER (incremental cost-effectiveness analysis).
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Figure 1 depicts the process of literature selection for this review. The initial search yielded 
224 abstracts. By screening of titles and abstracts, 197 studies were excluded because they 
were not cost-effectiveness studies or because they were about supporting strategies to 
increase the usage of IV rtPA, such as telemedicine or air transportation for stroke patients, 
and thus were excluded. In addition, review articles, editorial letters, abstracts, and 
commentaries were excluded (n=8). We completed full-text review of all articles that passed 
the initial titles and abstracts review and finalized the set of original research articles (n=16) 
for this study by further excluding 3 studies that were not original cost-effectiveness studies.
Cost-effective analysis is an economic evaluation method comparing both costs and health 
outcomes of alternative interventions.(17) Common health outcomes used in the literature 
include quality-adjusted life years (QALYs), life years gained, number of cases prevented, 
and mortality.(17) QALYs, which were developed in 1960’s for cost-effectiveness analyses, 
are measures of health considering both mortality and morbidity. QALYs are valued between 
0 and 1 per year, meaning 0 as death and 1 as perfect health.(18) Cost-effectiveness analysis 
using QALYs is also called as cost-utility analysis.(19) ICER, the main estimate in a cost-
effectiveness analysis, is derived by the difference in costs over the difference in health 
outcomes between alternative interventions. In this review, ICER is the difference in cost 
between IV rtPA treated group and non-IV rtPA group, i.e. incremental cost, over the 
differences in QALYs between them, i.e. incremental QALYs.
We analyzed the literature by: (1) model structure and main data sources, (2) study results, 
and (3) major limitations. For model structure and data sources, we examined perspective, 
modeling method, and intervention type, and main source of economic and clinical data. For 
study results, we summarized the cost-effectiveness results by various study time windows, 
time horizon, net-cost savings, QALYs gained, and ICER. Major limitations mentioned in 
each study were also summarized.
We used a cost-effectiveness quadrant diagram to demonstrate the costs and outcomes of an 
IV rtPA strategy compared with a non-rtPA strategy (Figure 2). The horizontal axis 
represents incremental QALYs associated with IV rtPA and the vertical axis represents the 
incremental cost associated with IV rtPA. For instance, the negative numbers in the vertical 
axis means that cost for a patient who received IV rtPA were lower than the cost for a patient 
who did not receive IV rtPA. When an estimated ICER is located in quadrant IV (lower 
right), IV rtPA is a cost-saving or a dominant strategy, i.e. higher QALYs with less cost. 
When an estimated ICER is located in quadrant I or III, the acceptance decision depends on 
value of the estimated ICER and an ICER threshold. In this paper, we used $50,000/QALY 
as a reference threshold. (20) If the estimated ICER is below the threshold, i.e., located 
under the dotted line in the Figure 2, we define that IV rtPA is a cost-effective strategy and 
adopt the IV rtPA strategy.
To compare ICERs from different countries, we derived 2014 US dollar value from all 
studies, which did not report ICERs in US dollars, by using consumer price indices (CPI) 
from the World Bank and purchasing power parity (PPP) exchange rate in 2014 from the 
Organisation for Economic Co-operation and Development (OECD).(21–23) The 2014 US 
dollar value was derived by multiplying CPI in 2014 at a study country by incremental costs 
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from a study, divided by CPI in a study year at a study country, and divided by a PPP 
exchange rate (national currency of study country per US dollar) in 2014 (Incremental costs 
from a study × (CPI in 2014 at a study country/CPI in a study year at a study country)/PPP 
exchange rate). When a study reported multiple ICERs from different time periods, we 
included ICERs from both a short-term (1 year) and a long-term (30 years or a lifetime) time 
period.
3. Results
Among 15 original articles reviewed, six studies were from the US(9, 24–28), two from the 
United Kingdom (UK)(29, 30), two from Australia(31, 32), two from China(33, 34), and one 
each from Canada(35), New Zealand(36), Denmark(37), and Spain(38). Nine of them used 
the payers’ perspective or health care system perspective, and four studies used the societal 
perspective while two studies did not clearly mention it.
In Table 1, nine of 15 studies investigated the cost-effectiveness of IV rtPA therapy within 0–
3 hours after stroke onset(9, 24, 26, 28, 30, 32, 35, 37, 38), two studies within 3–4.5 
hours(25, 27), three studies within 0–4.5 hours(31, 34, 36), and one study within 0–6 
hours(29, 33) (Figure 1). The first study that examined cost-effectiveness of IV rtPA was 
published in 1998, two years after the FDA approval.(9) Eight out of 16 studies were 
published between 2011 and 2016. Among them, the five studies were the studies of IV rtPA 
within 3–4.5 hours or 0–4.5 hours after the onset of stroke.(25, 27, 31, 34, 36) The 
remaining three studies published during this period were US studies looking at the 0–3 
hours’ time window to investigate up-to-date cost-effectiveness of IV rtPA(24) or state 
specific cost-effectiveness of IV rtPA(26), and Chinese study examining the 0–6 hours cost-
effectiveness of IV rtPA(33).
The reviewed studies used various sources of data for analyses. Main data sources were 
published data or literature. When published data were not available, data from hospitals or 
panel survey data were used.(30, 38) For economic data, ten studies used both previously 
published literature and data from their own collection or analyses. Three studies used 
previously published literature data only and two studies used data from the authors’ own 
collection or analyses. For clinical data, only five studies used data from both sources. In 
addition, three studies were from a small community based study.
All studies consistently showed that IV rtPA improved QALYs (Table 2), even some 
showing marginal improvement of QALYs. Sinclair et al. showed exceptionally high 
improvement of QALYs associated with IV rtPA (3.46 QALYs per patient).(35) Because of 
the complexity of the cost-effectiveness model and multiple input sources, there could be 
multiple reasons of high QALYs improvement in this study.
The impact of IV rtPA on cost was ambiguous and varied by time window and study time 
horizon. In the US, two of the six studies examined the cost-effectiveness of IV rtPA within 
the 3–4.5 hour time window. Use of IV rtPA within 3–4.5 hours after the onset of stroke 
increased costs ($1,495 – $6,050) but improved QALYs (0.24–0.28) over the lifetime. The 
estimated ICERs ($6,255/QALY–$21,978/QALY) showed the therapy was cost-effective 
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using the $50,000/QALY threshold. The remaining four studies in the US showed that IV 
rtPA within 0–3 hours after onset of stroke was a dominant strategy, i.e. cost saving and 
QALYs gained.
The results from non-US studies using IV rtPA within 0–3 hours were consistent with the 
results from the US studies. One exception, which showed an ICER marginally above an 
ICER threshold of $50,000/QALY at the first year ($55,591 per QALY), is the Danish study 
by Ehlers and colleagues that examined a range of time periods and showed that IV rtPA 
within 0–3 hours after the onset of stroke with 24-hour in-house MRI imaging and 
neurology coverage increased cost for the first and the second year after stroke.(37) IV rtPA, 
however, became a dominant strategy after the third year and the 30 years estimates also 
indicated the IV rtPA as a dominant strategy.(37) Results from three non-US studies 
examining the cost-effectiveness of IV rtPA within 0–4.5 hours showed that IV rtPA 
increased cost but was cost-effective with an ICER threshold of $50,000/QALY. The UK 
study by Sandercock and co-workers showed that IV rtPA within 6 hours of symptom onset 
increased cost and the ICER was £13,581 per QALY ($25,045/QALY in 2012 dollars) for 
the first year after the stroke, but over the lifetime the therapy was a dominant strategy.(29) 
The Chinese study by Yan and co-workers also showed that IV rtPA within 6 hours 
increased both cost and utility and cost-effective within 14 days after the stroke. (33)
All of the ICERs were located in quadrant I or IV (Figure 3). Lifetime ICERs of IV rtPA 
within 0–3 hours or 0–4.5 hours were located in quadrant IV, and therefore using IV rtPA 
was a dominant strategy. The ICER of IV rtPA within 0–3 hours from Sinclair et al. was not 
shown in the Figure 3 because of space limitation but the ICER was located in quadrant IV.
(35) The ICERs from studies that examined IV rtPA within 3–4.5 hours were located in 
quadrant I and under the threshold line, thus IV rtPA was a cost-effective strategy in this 
scenario. The impact of IV rtPA on cost in the first year was ambiguous but IV rtPA was still 
a short-term dominant or a cost-effective strategy from most studies.
We summarized major limitations of the literature (Table 3). The most common limitation 
was insufficient data for accurate cost-effectiveness estimates. Some studies mentioned a 
lack of generalizability because of data limitations.(24–26, 28, 33, 35) It was also pointed 
out that some studies used multiple data sources because of limited data.(24, 25) Lack of 
long-term mortality and cost data as well as insufficient up-to-date outcome and cost data 
were also mentioned as limitations.(24, 26, 37)
4. Discussion
This review investigated studies about cost-effectiveness of IV rtPA for treating acute 
ischemic stroke patient. IV rtPA within 0–3 hours after the onset of stroke was cost-saving 
while improving QALYs during life-time. The finding about the cost-effectiveness of IV 
rtPA within 0–3 hours after the onset of stroke is consistent with previous reviews.(10–12) 
However, the most recent review was published before AHA/ASA released the updated 
guidelines with extended time window. In the review, we found that IV rtPA within 0–4.5 
hours or within 3–4.5 hours after the onset of stroke was cost-saving or cost-effective. 
Although some studies showed that IV rtPA within 0–4.5 hours or within 3–4.5 hours after 
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the onset of stroke increased cost, it was a cost-effective strategy. The review results 
emphasize the importance of reducing door-to-needle time for acute ischemic stroke 
patients.
In addition to time windows, some other factors may lead to heterogeneity in study results. 
For example, the study perspective affects the cost-effectiveness of IV rtPA. Health care 
payers’ perspective considered only direct medical cost while societal perspective included 
both direct medical cost and indirect cost, such as productivity loss and informal caregiving 
costs. IV rtPA is expected to decrease indirect costs associated with stroke while IV rtPA is 
known as reducing the short-term disability rate.(7–9, 25) Considering indirect costs could 
improve the ICER for IV rtPA within 3–4.5 hours after stroke or make IV rtPA a dominant 
strategy. Time horizon may also significantly affect the cost-effectiveness of IV rtPA. All the 
studies consistently concluded that IV rtPA increased short-term (1 year) cost. However, IV 
rtPA reduced long-term cost (lifetime or 30 years) because of lower rehabilitation and 
disability associated cost cost among IV rtPA patients.
A main strength of reviewed studies is a timely research using the most recent available 
costs and outcomes from published secondary sources or primary data collection as inputs 
for evaluations. These inputs changed over time because of new medical technology for 
treating acute ischemic stroke and updated recommendations or guidelines. After releasing 
the updated guidelines from AHA/ASA in 2009 and other organizations in Europe and 
Australia on the extended time window for IV rtPA therapy (13–16), a number of 
publications (n=6) have examined the extended time window in the past 6 years.
Some common limitations of the studies, however, were also observed. One of the main 
limitations in the studies was that indirect costs, such as productivity loss and informal 
caregiving cost, were usually not included in the cost analyses. The proportion of indirect 
costs for stroke is significant.(39) A literature review showed that the median proportion of 
indirect costs was 32% of the total cost of stroke.(39) However, most studies chose the 
healthcare perspective or payers’ perspective, which did not consider indirect costs. 
Moreover, studies using the societal perspective did not include indirect costs(26, 27), or 
included informal caregiving cost only(38). None of the studies included productivity loss as 
a part of cost. When current cost-effectiveness models assumed an elderly cohort, 
productivity loss among stroke survivors may be negligible. However, stroke onset among 
young adults has been increasing (40) and productivity loss could be a large burden for 
young stroke survivors with disabilities. For better cost-effectiveness evaluation, indirect 
cost should be considered as a part of cost in the analyses.
Next, most of lifetime and long-term effectiveness data, including QALYs of disabled stroke 
survivors, incidence of recurrent stroke among stroke survivors, and one year mortality, were 
limited as well as outdated although all studies tried to use the most up-to-date data 
available. Most studies in the 2010’s still used QALYs data from the 1990’s studies.(24–27). 
Although cost data, especially long-term cost data, could hardly be free from outdated data, 
the reviewed studies tried to use recent cost data or at least adjusted cost to current currency 
value by using consumer price index (CPI) to alleviate concerns regarding outdated data. 
Lastly, there were some inconsistencies because of using multiple data sources. For instance, 
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QALYs by disability status were not well-developed in the literature. Thus, QALYs of 
disabled and non-disabled stroke survivors were obtained from different data sources.(24, 
25) In addition, most of the cost data were not collected within clinical trials, leading to a 
lack of consistency within a study.
Potential research areas to make up for these limitations as well as to improve the quality of 
research remain. Despite robust results from sensitivity analyses, developing high quality 
data sources is still important for future efforts. Developing long-term follow-up trials 
among stroke survivors and research in long-term cost and effectiveness is most needed. 
Published large scale effectiveness data from the real-world, including cost as a sub-
component, and studies which investigate those data are also needed. There are needs for 
indirect cost data and cost-effectiveness studies from the societal perspective to better 
understand societal impact of IV rtPA therapy. Concurrently, better models with multiple age 
cohorts would be useful to identify the impact of IV rtPA on different age cohorts. Boudreau 
et al. partly shows how much the ICER could be different by age.(25) Another future 
research area would be to examine the impact of the age or severity of stroke on ICER of IV 
rtPA treatment.
There were few studies in developing countries, likely because of a lack of infrastructure to 
provide IV rtPA. The incidence of stroke in the developing world has increased since 1970s, 
with 85% of stroke deaths worldwide occurring in developing countries.(41) We found only 
two studies of cost-effectiveness of IV rtPA from developing countries (33, 34). To better 
understand the cost-effectiveness of IV rtPA worldwide, more studies from countries in 
Africa, Latin America, and Asia would be useful.
In this review, we did not include studies examining cost-effectiveness of strategies to 
improve the underutilization of IV rtPA. Despite strong evidence of better clinical outcomes 
associated with IV rtPA, IV rtPA remains underutilized among acute ischemic stroke 
patients.(42) Only 3.4% to 5.2% of stroke patients received rtPA therapy in the US in 2009.
(43) Telestroke, air transport, and certified stroke centers have been discussed as strategies to 
improve the utilization of IV rtPA. The implementation of those strategies may improve IV 
rtPA utilization but require additional costs. However, reviewed studies assumed that there 
were no additional costs to provide patient access to IV rtPA. Further cost-effectiveness 
studies including implementation costs are needed to support utilization of IV rtPA.
5. Conclusions
This study found that the IV rtPA was a dominant strategy for those who received the 
therapy within 0–3 hours after the onset of stroke and a cost-effective strategy for those who 
received the therapy within 3–4.5 hours after stroke in long-term compared to traditional 
treatment for acute ischemic stroke patients without IV rtPA. This review provides 
considerable support for further development of interventions to promote IV rtPA use. To 
better evaluate cost-effectiveness of IV rtPA, establishing relevant clinical and cost data 
sources and developing evaluation, including program costs, may be useful to improve the 
access to and use of IV rtPA.
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IV rtPA Intravenous recombinant tissue plasminogen activator
IV Intravenous
AHA/ASA American Heart Association/American Stroke Association
QALY quality adjusted life years
ICER Incremental cost-effectiveness analysis
CPI Consumer price indices
PPP Purchasing power parity
OECD Organisation for Economic Co-operation and Development
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Selection of studies on cost-effectiveness analysis of recombinant tissue plasminogen 
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Conceptual framework of cost-effectiveness of recombinant tissue plasminogen activator 
(rtPA) therapy
Joo et al. Page 12














Summary of incremental cost-effectiveness ratios (ICERs) of rtPA therapy from the 
literature
Notes:
x : The first year incremental costs and QALYs from rtPA therapy
△: Lifetime incremental costs and QALYs from rtPA therapy within 3–4.5 hours after onset 
of stroke
● : Lifetime or 30 years’ incremental costs and QALYs from rtPA therapy within 0–3, 0–
4.5, or 0–6 hours after onset of stroke
For studies with non-US currency, 2014 US dollar values were derived by using consumer 
price indices of study countries in the years of costs and in 2014 from the World Bank and 
purchasing power parity (PPP) exchange rate in 2014 from the Organisation for Economic 
Co-operation and Development (OECD). The ICER from Sinclair et al. was not shown in the 
graph because of limited space.(35) IV rtPA was a dominant strategy from Sinclair et al..(35)
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Table 3
Major limitations listed in the cost-effectiveness studies of rtPA for acute ischemic stroke
Study/Year/Country Limitations
Yan et al. (2015), China • The medical costs did not include the cost after discharge.
• The study used charges not real costs.
• The study used data from a single hospital in China.
Boudreau et al.(24) (2014), US • The results were specific to the assumptions and the data used.
• QALYs were derived by using multiple inconsistent studies.
• Long-term cost, QALYs, disabilities, and mortality data were limited and dated.
Pan et al.(34) (2014), China • Inaccurate estimate for each component of tPA associated cost
• Informal caregiving costs were not included.
• The study did not model changes in functional status from causes other than stroke.
• The study used the efficacy and the utility data from studies in developed countries.
Boudreau et al.(25) (2013), US • The results are specific to the assumptions and the data used.
• The data are from numerous published studies including clinical trials.
Kazley et al.(26) (2013), US (SC) • The study examined only a single state.
• The assumptions and data used in the study did not fully represent the clinical practice 
situation.
• Data do not represent the current year.
• The study may underestimate the benefit because of previously validated model with 
conservative estimates.
• The study only considered treatment within 3 hours after stroke onset. (not up to 4.5 
hours)
Tan Tanny et al.(31) (2013), 
Australia
• The study assumed that survival and quality of life would not change between 90 days 
and 12 months after stroke.
• Efficacy data were drawn from analyses of studies of rtPA being given between 3 and 4.5 
hours (not rtPA within 4.5 hours).
Tung et al.(27) (2011), US • Input parameters were best estimates from previously published data.
• The study did not model changes in functional status from causes other than stroke.
Johnston (28)(2010), US • The results depended on a single cost-utility analysis that required a number of uncertain 
assumptions.
Ehlers et al.(37)(2007), Denmark • The lack of adequate long-term data.
Mar et al.(38)(2005), Spain • The use of proxies to answer the questionnaire.
Chambers et al.(30) (2002), UK • Limited published data about the cost of care for stroke survivors.
• Indirect costs, informal care costs, and quality of life of other family members were 
excluded from the model.
• No sufficient published information on resource use, rates of recurrence, or disability and 
mortality by age group.
• The variability of parameter estimates is not well known.
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Study/Year/Country Limitations
Sinclair et al.(35) (2001), Canada • Short-term hospitalization cost based on a small sample size of 22 patients from a single 
center (generalizability).
• There was a difficulty in determining the costs of stroke care and services in Canada on a 
‘per patient basis’.
• The study used a point estimate without a formal quantitative estimate of its precision.
Fagan et al.(9) (1998), US • The study used a placebo group from the NINDS rtPA Stroke Trial as the source of data 
for some aspects of the cost analysis.
• The protocol precluded antithrombotic therapy in the first 24 hours after stroke onset, 
which may affect cost and health outcomes.
Note: Three studies (Te Ao et al.(36), Moodie et al.(32), Sandercock et al.(29)) did not list limitations.
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